Where does Catalyst Pharmaceutical's cash flow data come from?

Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$221.32M+3.3%	$214.33M-1.5%	$217.56M+4.3%	$208.67M+5.7%	$197.35M+20.4%
Depreciation and amortization	$330K-12.0%	$375K-10.1%	$417K-7.5%	$451K+5.9%	$426K+7.3%
Stock-based compensation	$25.19M+1.7%	$24.78M+2.0%	$24.29M+5.4%	$23.04M+16.1%	$19.85M-10.8%
Deferred income taxes	——	——	——	——	——
Change in accounts receivable	$64.97M-2.2%	$66.4M+24.0%	$53.55M+280%	$14.09M—	——
Change in inventories	$15.62M-13.7%	$18.09M—	——	——	——
Change in accounts payable	——	——	——	-$1.59M-270%	$936K-47.9%
Change in accrued liabilities	$17.51M-27.5%	$24.16M-13.2%	$27.85M-19.6%	$34.66M-19.1%	$42.82M-20.5%
Change in other assets	——	——	$9.74M—	——	——
Amortization of intangible assets	$37.86M+1.0%	$37.5M+0.3%	$37.38M0.0%	$37.38M0.0%	$37.38M0.0%
Net gains (losses) on investments	$3.08M+217%	$972K-77.5%	$4.33M-47.1%	$8.17M-7.8%	$8.86M+74.6%
Change in operating lease liabilities	-$410K-2.2%	-$401K-2.0%	-$393K-2.1%	-$385K-2.1%	-$377K-2.2%
Net cash from operating activities	$208.21M-0.2%	$208.67M-11.1%	$234.66M-14.7%	$275.09M+2.7%	$267.93M+11.7%
Capital expenditures	$85K+46.6%	$58K-49.1%	$114K-69.4%	$373K+4.5%	$357K-35.8%
Purchases of intangible assets	——	——	——	——	——
Purchases of equity securities	——	$0—	$0—	——	——
Acquired in-process research and development	——	$0—	$0—	——	——
Net cash from investing activities	-$85K-46.6%	-$58K+49.1%	-$114K+69.4%	-$373K-4.5%	-$357K+35.8%
Repurchases of common stock	$33.55M+32.6%	$25.3M+33.3%	$18.98M+50.0%	$12.65M+100%	$6.33M—
Proceeds from issuance of common stock	$3.3M—	$0—	——	——	——
Taxes paid for net share settlement	$1.43M-19.2%	$1.77M+33.8%	$1.33M—	——	——
Net cash from financing activities	-$32.93M-93.8%	-$16.99M-231%	$13.02M+55.6%	$8.37M-3.3%	$8.65M-94.1%
Net increase (decrease) in cash	$175.2M-8.6%	$191.62M-22.6%	$247.56M-10.7%	$277.11M+2.5%	$270.25M-28.9%
Interest paid	$503K+7.9%	$466K+8.4%	$430K-70.7%	$1.47M+2.6%	$1.43M+2.7%
Income taxes paid	$73.19M+1.7%	$71.99M+0.1%	$71.9M-2.3%	$73.59M—	——
Accretion Of Discount	$425K+21.4%	$350K+28.2%	$273K-78.3%	$1.26M+20.2%	$1.05M+25.5%
Amortization of capitalized software and acquired intangible assets	$37.86M+1.0%	$37.5M+0.3%	$37.38M0.0%	$37.38M0.0%	$37.38M0.0%
Depreciation	$330K-12.0%	$375K-10.1%	$417K-7.5%	$451K+5.9%	$426K+7.3%
Equity Securities, FV-NI, Gain (Loss)	$3.08M+217%	$972K-77.5%	$4.33M-47.1%	$8.17M-7.8%	$8.86M+74.6%
Accrued expenses and other liabilities	$17.51M-27.5%	$24.16M-13.2%	$27.85M-19.6%	$34.66M-19.1%	$42.82M-20.5%
Increase (Decrease) in Deferred Income Taxes	——	——	——	——	——
Operating lease liabilities	-$410K-2.2%	-$401K-2.0%	-$393K-2.1%	-$385K-2.1%	-$377K-2.2%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$9.74M—	——	——
Non Cash Change In Right Of Use Asset	$300K+1.7%	$295K+1.4%	$291K+1.4%	$287K+1.8%	$282K+1.4%
Payment Of Liabilities Arising From Asset Acquisition	$4.8M+4.7%	$4.59M+3.5%	$4.43M-66.5%	$13.24M+1.9%	$13M+0.9%
Accrued Milestone Payment Classified As License And Acquired Intangibles Net	——	$12.5M+33.3%	$9.38M+50.0%	$6.25M+100%	$3.13M—
Increase Decrease In Operating Lease Liability	-$410K-2.2%	-$401K-2.0%	-$393K-2.1%	-$385K-2.1%	-$377K-2.2%
Free cash flow	$208.13M-0.2%	$208.61M-11.1%	$234.54M-14.6%	$274.72M+2.7%	$267.57M+11.8%
Free cash flow	$208.13M-0.2%	$208.61M-11.1%	$234.54M-14.6%	$274.72M+2.7%	$267.57M+11.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Catalyst Pharmaceutical's cash flow data come from?: Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.